Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 + Doxorubicin in Advanced Soft Tissue Sarcoma
NCT02255110Phase 2Terminated
- Sponsor
- Merck KGaA
- Start
- Dec 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of evofosfamide in soft tissue sarcoma (STS), sponsored by Merck KGaA. Primary endpoint: Progression Free Survival by Independent Central Review at 6 months. Started Dec 2014; status: terminated.
02
Drugs
evofosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02255110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02255110.